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ABSTRACT 
STUDY OF GAIN OF FUNCTION MUTATION IN P53-NULL ASTROCYTES 
By Sang H. Choi 
A thesis submitted in partial fulfillment of the requirement for the degree of Master of 
Science at Virginia Commonwealth University. 
Virginia Commonwealth University, 2000. 
Major Director: Oliver Bogler, Ph.D., Assistant Professor, Department of Anatomy and 
Division of Neurosurgery. 
A number of recent studies suggest that expression of mutant p53 with mutations 
in certain codons show a gain of function and some of the characteristics of an 
oncoprotein. In order to study gain of function mutation and eliminate the potential of a 
dominant negative interaction with endogenous wild type p53 protein, p53 knockout 
mouse astrocytes were used. A retrovirus system was used to introduce mutant p53 
genes into these p53-null astrocytes. Immunohistochemical staining and western blot 
experiments showed the expression of mutant p53 protein in these cells after infection 
with the mutant p53 retroviruses. Cell growth experiment did not suggest growth 
advantages for mutant p53 expressing astrocytes over vector control cells. Data from 
clonogenic survival assays following exposure to etoposide or cisplatin suggested that 
mutant p53 expressing cells with a point mutation at codon 273 may be resistant to 
VI 
apoptosis induced by etoposide. In contrast, p53 with a point mutation at codon 248 may 
sensitize cells to the apoptotic effects of etoposide and cisplatin. 
Introduction 
In spite of much effort and advances in cancer research, resistance of tumor cells to 
radiation and chemotherapy remains a significant obstacle in the treatment of cancer. 
Most cancer patients continue to receive highly toxic drngs, and some tumors fail to 
respond to these drngs. It is apparent that many anticancer reagents induce apoptosis, or 
programmed cell death 1 • However, the mechanisms that determine drng chemosensitivity 
and resistance remain poorly understood. Therefore, there are efforts to identify 
molecular defects in cancer cells, hoping that this information will ultimately suggest 
strategies for improved cancer therapy. 
Mutations in the p53 tumor suppressor gene occur in more than 50% of human 
malignancies and in diverse tumor types2 . This implies that loss of p53 function is 
central to tumor development. Wild type p53 is a transcription factor that can induce 
growth arrest or apoptosis3
• It seems that the ability of p53 to prevent cell growth is 
pivotal to its tumor suppressor functions. For example, y-irradiation of fibroblasts 
produces cell cycle arrest in the G 1 and G2 phase of the cell cycle (G 1 check point 
requires functional p53). However, cells with mutant p53 proliferate into S phase 
following the irradiation and DNA damage3. Loss of G 1 check point and DNA integrity 
could increase the mutation rate, allowing mutant p53 tumor cells to evolve more rapidly. 
In general, p53 mutation is associated with more aggressive cancers of higher tumor 
grade, correlating with reduced patient survival rate 1 .4 . 
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P53 is a sequence-specific DNA binding protein, and its binding to DNA is necessary 
for wild type p53's tumor suppressing function3 . As depicted in Figure 1, the p53 
protein has five functionally distinct domains: a transcriptional activation domain 
(residues 1-42), a praline-rich domain involved in apoptosis (residues 60-93), a sequence 
specific DNA binding domain (residues 120-290), a C-terminal oligomerization domain 
(residues 310-353), and a regulatory domain (residues 360-393)5. The sequence specific 
DNA binding domain is located in the central part of the molecule covering conserved 
domains 11-V (Figure 1)6. DNA binding by p53 is regulated and requires activators7 . 
These activators can change the conformation of p53 and make the DNA binding sites 
available. Transcriptional regulation by p53 depends on the presence of the C-terminal 
oligomerization domains . The C-terminal oligomerization domain contains the major 
nuclear localization signals and mediates tetramer formation of p539. In addition, the C­
terminal region has a non-sequence specific nucleic acid binding domains . Many genes 
containing p53-binding sites in the promoter or an intron region have been identified and 
include p2 l, gadd45, mdm2, and bax 10. These genes translate into proteins that play roles 
in growth control, and it indicates that the sequence-specific DNA binding of wild type 
p53 protein is essential for its tumor suppressing function. 
In human tumors, the majority of p53 gene alterations are missense mutations 7. The 
frequency of mutation at particular codons differs slightly among tumor types. For 
example, codon 175 is mutated most frequently in colon cancer whereas brain has codon 
273 commonly mutated 7. In general, p53 mutation found in tumors usually occur within 
the central part of the molecule, and the mutant p53 proteins are defective in the sequence 
specific DNA binding region9. However, there is evidence that some mutants bind to 
DNA weakly and nonspecifically 11 • 
There are two different classes of missense mutations in p53 protein: mutation in 
residues that make direct contact with DNA (R273H and R248W) and mutations in 
residues that alter the overall tertiary structure of the protein when they are mutated 
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(Rl 75H)6 . R273H and R248W are involved in contacting the minor groove and 
phosphate backbone of the DNA backbone, respectively6. Mutations at those codons 
alter the sequence specificity of DNA binding, without preventing it altogether. R 175H 
plays role in stabilizing the tertiary structure, and its mutants are strongly denatured to the 
extent that DNA binding is compromised. 
A remarkable difference between the p53 gene and other tumor suppressor gene is 
that it usually gives rise to mutated proteins whereas other tumor suppressor genes 
frequently result in complete loss of function with no or only a truncated protein 
expressed 12. This indicates that mutant p53 is not functionally neutral but contributes to 
tumorigenesis. Furthermore, mutant p53 can be functionally characterized in three ways: 
loss of function, dominant negative function, and gain of function. Loss of function can 
be characterized by the fact that mutant p53 loses the ability of wild type p53 to interact 
with the specific sequences of DNA and can not induce growth arrest in response to DNA 
damage. In other contexts, mutant p53 protein can form oligomeric complexes with the 
wild type p53 protein (heterotetramer) and block wild type's ability to function as a 
tumor suppressor. Lastly, in vivo and in vitro studies with p53 knock out cells reveal that 
certain mutants possess novel oncogenic functions that operate independently of wild 
type function. 
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The existence of gain of function by p53 protein is further supported by accumulation 
of mutant p53 proteins to high levels in many cancer cells although wild type p53 protein 
is relatively unstable 12• It is found that many transformed cell lines, including primary 
human tumor cells from patients with various types of tumors contain an elevated level of 
p53, whereas non-transformed cells contain only small amount of the protein. This 
difference may be attributed to stabilization of the mutant p53 protein in transformed 
cells. Other studies showed that mutant p53 can transactivate promoters of cellular 
growth related genes in culture such as epidermal growth factor receptor (EGFR), 
vascular endothelial growth factor (VEGF), and basic fibroblast growth factor (bFGF)12• 
13 Mutant p53 proteins can also transactivate the multi-drug resistance gene (MDR-1) 14' 
15 Two residues from N-terminal transactivation domain, leu-22 and trp-23 are required 
for the transactivation of MDR-1 16 • These results strengthen the notion that at least 
certain mutant p53 proteins gain transforming potential. 
One aspect of potential clinical importance of gain of function p53 mutation is its 
ability to confer increased resistance to chemo- and radio-therapy on the tumor cell. 
Many studies have shown that the presence of a p53 mutation was found to predict worse 
prognosis and reduced response to therapy in many tumors. For normal cells, DNA 
damage caused by chemotherapy or radiotherapy is sensed by wild type p53, which in 
tum induces cell growth arrest or apoptosis 17• Furthermore, introduction of wt p53 by 
adenovirus sensitized lung and glioma cancer cells (without endogenous wt p53) to 
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cisplatin and adriamycin 18 • However, introducing wt p53 by adenovirus to cancer cell 
lines with endogenous wild type had mixed results, varying among cell lines 18 . In 
contrast to normal cells with wild type p53, certain p53 mutant cells may have a selective 
survival advantage during chemo- and radiation therapy. For example, p53-null H 1299 
lung adenocarcinoma cells transfected with a p53His 175 mutant gene recovered 
preferentially from etoposide treatment 19• Moreover, same mutant protein reduced 
substantially the rate of etoposide-induced apoptosis. However, there are some reports 
suggesting that p53 status may not correlate with chemosensitivit/0. Other studies even 
argue that loss of wild type p53 increases sensitivity to chemotherapy 18• Interestingly, 
forced expression of mutant p53 in glioma cells enhanced the toxicity of some drugs but 
attenuated the effects of others 21. These results suggest thac response of p53 mutant cells 
to certain chemotherapy may be mutation and cell type specific. 
Loss and mutation of wild type p53 is the earliest genetic event detected in the 
tumorigenesis of astrocytomas4 . In addition, malignant progression in astroytes is widely 
regarded as a multistep process resulting in deregulation of growth control33. Studies of 
in vitro and in vivo growth and transformation showed that early passage p53-null 
astrocytes achieved more rapid growth than wild type p53 and p53 +t- cells. Although 
early passage p53-null cells were not transformed, continued passaging showed mutistep 
progression toward malignancy. In the same study, it was found that loss of wild type 
p53 promotes genomic instability. Furthermore, it was found that early passage p53-null 
astrocytes could not form colonies in soft agarose but gained this capability after 10 
passages34. Later study showed that p53-null astrocytes grown in DMEM-FCS or 
DMEM-EGF were able to form tumors after 40-50 population doublings. However, 
astrocytes grown in DMEM-bFGF never formed tumor, suggesting that malignant 
transformation of p53-null astrocytes may be modulated by environmental influences32 . 
Loss of wild type p53 activity could potentially account for increased chemo- and 
radio-resistance of tumors with p53 mutations. However, it might be possible that 
increased resistance may be due to direct protective effects of mutant proteins as shown 
with H1299 cells. To test this notion, we introduced p53 mutant gene to p53-null 
astrocytes, eliminating the effects of dominant negative function by mutant p53. 
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Methods and Materials 
Retrovirus vectors were used to express mutant p53 protein in p53-null astrocytes. To 
make retrovirus, 293 GP cells were co-transfected with VSVG plasmids and bi-cistronic 
IRES vectors encoding p53 mutant genes or a p53 wild type gene and the zeocin 
resistance gene. CaC12 transfections were done using a standard protocol
22 P53 mutants 
included R273H, R248W, R l75H, V l43A, and vector control (numbers indicate mutated 
codon position and amino acids are indicated by the one letter code, with the one before 
the number indicating the original, and the one after the number the mutant). 
Retroviruses were harvested 48 hours later and were subsequently frozen in -80°C 
freezer. Retroviral infection was done by first plating 40,000 p53-null ASTl 1.9 cells per 
T25 flask. One day after plating cells, all the medium was removed, and I ml of 
retroviral stock and 1 ul of polybrene at a final concentration of 8 ug/ml were added to 
the flask. Two hours later, retroviral stock was removed, and fresh medium was added. 
This procedure was repeated next day. Two days after the infection, the cells were 
passaged into a T75 flask and selected using zeocin (300 ug/ml). After about two weeks 
of selection, viable cells were replated and expanded into cell lines by continual growth 
in selective medium. DMEM with 10% FCS, L-glutamine, P/S, and zeocin (300ug/ml) 
was used as medium to maintain the cell cultures. 
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Expression of p53 mutant proteins in the infected astrocytes was confirmed by 
western blot analysis and immunohistochemical staining using human p53-specific 
monoclonal antibody PAbl801 (Ab-2) from Calbiochem. For immunohistochemical 
staining, cells were fixed with methanol for 20 minutes at -20°C. Cells were stained with 
p53 primary antibody (Ab-2) at room temperature for 40 minutes (at a concentration of 
1: 100). Cells were washed with Hank's Solution (HBSS), and stained with fluorescein 
labeled secondary antibody (goat anti-mouse Ab at concentration of I: I 00) from 
Southern Biotech. 
For western blot analysis, cells were first washed with PBS and centrifuged. 
Then the cells were resuspended with 60 ul of 2X Laemrnli's buffer. They were heated in 
a boiling bath for 5 minutes. 15 ul of each sample was loaded on a I 0% SDS gel with 
SDS Page low range standard (BioRad). Electrophoresis was run at 50-60 mA for about 
one hour, and separated samples were transferred to a PVDF membrane with Western 
transfer buffer (50mM Tris, 380mM glycine, 0.1 % SDS, 20% MeOH) and Biorad 
transfer assembly. Western transfer was run at 95V at 4°C for one hour. Western blots 
were blocked for one hour with 30 ml IX TBS, 0.9g BSA. After rinsing with IX TBS, 
1 ° antibody solution (20 ul p53 Ab-2, 30ml IX TBS, 0.3g BSA, 30ul Tween20, Biorad) 
was applied for overnight. Next day, transfer membrane was washed with IX TBS, and 
diluted 2° antibody solution (Biorad; goat anti-rabbit lgG, 33ul/l 00ml) was added. After 
one hour, 200ul of Biorad Immun-Star Substrate was applied, and the membrane was 
placed between two sheets of transparency paper before the exposure to Kodak BioMax 
film for 30-60 seconds. 
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Cell growth rates were measured by counting cells at 2, 4, 6 days after plating 
2,000 cells per well in a 12 well dish. Cells were counted using a hemocytometer (Fisher 
Scientific) under the microscope. 
For apoptosis experiments, 500,000 cells were plated per 10cm culture dish with 
four 12 mm round coverslips. After one day, cells were treated with etoposide (Sigma) 
or with cisplatin (Sigma) at concentration of 5.9 ug/ml and 2.5 ug/ml respectively. 
Zeocin was not added with the drugs. Stock solution of etoposide was made with DMSO 
at concentration of 5.9 mg/ml. Stock solution of cisplatin was made with NaCl (0.6 
mg/ml) solution at concentration of 1.25 mg/ml. Etoposide treated cells were stained 
with Annexin V and Hoechst nuclear stain a day after the drug treatment. Cisplatin 
treated cells were stained two days after the treatment. For double staining with Annexin 
V- FITC (Pharmingen) and Hoechst stain, cells were stained with Annexin Vat 
concentration of 1: 100 for 40 minutes. Cells were washed with Annexin V binding 
buffer ( IOX binding buffer is composed ofO. l M Hepes/NaOH, 1.4M NaCl, 25mM 
CaC12, and pH 7.4) and PBS and were fixed with 4% Paraformaldehyde for 10 minutes. 
After washing cells with PBS, cells were stained with Hoechst stain (2 ug/ml) for 5 
minutes. To measure percentage of apoptotic cells, Annexin V stained apoptotic cells 
were counted against two hundred Hoechst stained cells. 
Clonogenicity assays were done by plating 200,000 cells per 10 cm culture dish. 
After one day, three different concentrations of drug were applied to the cells without 
zeocin (2.95 ug/ml, 1.5 ug/ml, 0.7 ug/ml for etoposide, and 1.25 ug/ml, 0.6 ug/ml, 0.3 
ug/ml for cisplatin). Two days after the drug treatment, cells were replated into two 10 
cm culture dishes. Cells were fed with zeocin selective medium (300 ug/ml) every two 
days. Twelve days after the drug treatment, cells were stained with crystal violet stain. 
For crystal violet stain, cells were fixed with methanol for IO minutes and stained with 
crystal violet stain for 10 minutes. After washing the cells in 10 cm culture dishes with 
distilled water, they were air dried, and individual colonies were counted. 
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Results 
Generation of ASTl 1.9 cell population expressing p53 mutants 
To study gain of function mutation of p53, various p53 mutants were introduced 
into a medium passage (P 17) p53 knockout astrocyte cell line (AST 11.9) using 
retroviruses. The p53 mutant genes had missense mutation at codon positions 273, 248, 
175, or 143. These p53 mutants will be referred as R273H, R248W, Rl75H, Vl43A 
(numbers indicate mutated codon position and amino acids are indicated by the one letter 
code; before the number is original, and after the number is mutant). The retroviral 
vector contained the zeocin resistance gene down stream of an internal ribosomal entry 
site (IRES), ensuring that both the zeocin resistance gene and the p53 genes were 
expressed (Figure 2). After infecting AST 11.9 cells with retrovirus, cells expressing 
vector control without a p53 gene, wild type or mutant p53 were selected and maintained 
in DMEM 10% FCS with 300 ug/ml zeocin. 
To make sure that zeocin selection was working properly, cells without zeocin resistance 
gene (no-infection-control) were also exposed to 300ug/ml zeocin. Within a week, no­
infection-control cells were killed while 20-30% of cells infected with mutant p53 
retrovirus survived and continued to grow. Interestingly, AST 11.9 cells infected with 
wild type p53 retrovirus (wild type p53 cells) were killed at an even faster rate than no-
12 
Internal Ribosome Entry Site 
Transcription 
mRNA 
Figure 2. Internal Ribosome Entry Site (IRES). Both the p53 gene and the drug resistance marker gene (zeocin) 
are transcribed into a single mRNA. Ribosome can enter the mRNA either at 5' end to translate the p53 gene or at 
the IRES to translate the zeocin resistant marker. This system ensures that both p53 gene and zeocin resistance 
marker are expressed in the infected cells. 
-
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infection-control cells (data not shown), suggesting that expression of wild type p53 in 
AST 11.9 cells induced apoptosis. No cells expressing wild type p53 survived. 
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Monoclonal antibody PAbl 801 was used for immunostaining and western blot 
analysis to confirm expression of p53. PAb 180 I is known to work with both human 
mutant and wild type p53. Irnmunohistostaining (Figure 3) reveals that 90-95% of p53 
mutant cells (after zeocin selection) express p53. These mutant cells show a predominant 
nuclear localization of p53. As predicted, vector control cells do not show any nuclear 
stain. Western blot analysis (Figure 4) also confirms this result. Mutant p53 cells 
(R273H, R248W, R 175H, and V 143A) show bands around 53 kDa, while vector control 
cells do not show the p53 band. 
Since cells expressing wild type p53 do not survive more than a week in culture, 
these cells were stained 48 hrs after the infection with wild type p53 retrovirus. 
However, these cells did not show any significant nuclear stain for p53 (data not shown). 
Positive control cells (infected with mutant p53 retrovirus) also did not score positive for 
p53 48, 72, and 96 hours after the infection. This result may suggest that these cells did 
not accumulate enough p53 to be visibly stained within that period of time. However, 
apparently cells infected with wild type p53 retrovirus expressed enough wild type p53 to 
prevent their outgrowth. 
Expression of mutant p53 does not confer a growth advantage on AST 11.9 cells 
Immunohistochemistry of AST 11.9 (p53 -1-) Infected with Mutant p53 
Retrovirus 
Figure 3. After zeocin selection, the astrocytes were stained with monoclonal p53 antibody. Mutant p53 astrocytes (143, 175, 
248, 273) show the nuclear p53 stain while vector control astrocytes show only the background stain. In addition, the nuclear 
p53 stain is seen in >98% of cells. 
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Figure 4. Western blot analysis shows the expression of p53 in mutant cell lines (Vl43A, Rl 75H, R248W, R273H) while 
there was no p53 band for vector control astrocytes. ;;: 
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It is known that mutant p53 can transactivate promotors of cellular growth related 
. 1 h ·ct 11 genes m cu tures sue as ep1 ermal growth factor receptor (EGFR) ·. However, this gain 
of function characteristic may be cell-specific. To test the notion that p53 mutant cells 
may display growth advantages, cells were plated in 12 well dishes in equal numbers. 
After 2, 4, and 6 days, the number of cells was counted using the hemocytometer. As 
shown in Figure 5, ASTl 1.9 cells expressing mutant p53 did not show significant growth 
advantages in cell culture over ASTl 1.9 cells lacking p53 (vector control cells). In 
addition, cells expressing Vl43A even showed a slightly slower growth rate than the 
vector control cells. 
AST 11.9 cells expressing certain mutant p53 proteins display protection against the 
apoptotic effect of etoposide 
Some studies have shown that p53 mutant cells confer resistance to 
chemotherapeutic drugs or radiation induced apoptosis. Furthermore, p53 with different 
point mutations expressed in the same cell line caused cells to behave differently in 
response to etoposide and cisplatin 19. To examine if mutant p53 cells show any 
resistance to chemotherapeutic drugs, different mutant p53 cells were treated with 
etoposide (5.9 ug/ml) or cisplatin (2.5 ug/ml). Etoposide is an inhibitor of topoisomerase 
II. It interferes with scission-reunion reaction of topoisomerase II and induces DNA 
lesions23 . Cisplatin is a positively charged molecule and forms intra- and interstrand 
crosslinks with DNA, thereby inhibiting DNA replication 24. One day or two days after 
Growth Rate of p53 Mutant Astrocytes 
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Figure 5. Each mutant astrocyte cell line was plated at low density (2000 cells per well) in a 12 well dish. Cells were 
taken off the dish and counted using hemocytometer at 2, 4, and 6 days after plating. Each data point represents the 
average of four separate experiments. 
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the drug treatment, coverslips were removed, and cells were double stained with Annexin 
V and Hoechst nuclear stain (Figure 6). Staining with Annexin V indicated that cells 
were undergoing apoptosis. Annex in V is a Ca2+ -dependent phospholipid-binding 
protein that has high affinity for the phospholipid phosphoserine (PS). In the early phase 
of apoptosis, the membrane PS is translocated from the inner leaflet of the plasma 
membrane to the outer leaflet, thereby exposing the PS to the external environment for 
Annexin V to bind25. Hoechst nuclear stain was used to count the total number of cells. 
The percentage of cells undergoing apoptosis is shown in Figures 7 and 8. 
About 15% of vector control cells were undergoing apoptosis one day after the 
treatment with etoposide (Figure 8). Most mutant cells (R248W, RI 75H, and Vl43A) did 
not show significant reduction in apoptosis. However, cells expressing R273H showed a 
notable reduction in apoptosis. It implies R273H may bestow a protective effect against 
etoposide induced apoptosis. In contrast, there was no significant protective effect of 
mutant p53 against cisplatin. As shown in Figure 7, only R273H and Rl75H show a 
slightly lower percentage of apoptotic cells than the vector control cells. In summary, 
only cells expressing R273H showed a protective effect against etoposide. However, 
mutant p53 did not confer significant resistance to the apoptotic effects of cisplatin. 
As shown in Figure 6, cells were allowed to recover for another 10 days after 
removing the coverslips. However, cells that remained in the 10cm dish never resumed 
growth as shown by crystal violet stain at day 13 (pictures not shown). That showed that 
although mutant p53 could protect astrocytes from apoptosis in high concentrations of 
drugs (5.9ug/ml for etoposide and 2.5 ug/ml for cisplatin), it did not allow them to 
Apoptosis Assay 
+ 
Treatment 
with 
The cells etoposide 
treated and 
with The cells cisplatin 
etoposide treated 
were with 
Cells stained cisplatin .. 'i'!..,. ':.tr were with were "!" Hoechst Stain $ stained annexin V stained 
{ with and with f<l> !.�� � f. crystal Hoechst annexin V � 'if,. violet stain and • $ 
Hoechst 
Control stain 
• 
Day1 was @ 
stained 
with 
crystal 
violet 
Figure 6. For apoptosis assay with annexin V stain, cells were plated on coverslips. Etoposide treated cells were stained 
with annexin V and Hoechst stain on Day 2 with control cells. Cisplatin treated cells were stained on Day 3. The number 
of apoptotic cells were counted using annexin V stain for every 200 cells counted under UV using Hoechst stain. 
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Figure 7. Percentage of apoptotic cells was calculated by using the number of apoptotic cells stained with annexin V for 
every 200 cells stained with Hoechst stain under the same view under the microscope. Mutant cells were treated with 2.5 
ug/ml of cisplatin for 48 hours before staining. Untreated cells ( control) were stained and counted at the same time with 
the cisplatin treated cells. Each data point represents the average of four separate experiments. 
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Figure 8. Percentage of apoptotic cells is calculated by using the same method as cisplatin. Mutant cells were treated with 
5.9 ug/ml of etoposide for 24 hours before staining. Untreated cells ( control) were stained and counted at the same time 
with cisplatin treated cells. Each data point represents the average of four separate experiments. 
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survive and grow. To measure this directly, we designed a clonogenic survival assay 
experiment. 
Certain mutant p53 cells recover from etoposide and resume growth while others show 
sensitization to etoposide and cisplatin 
Since certain mutant p53 proteins can provide increased chemoresistance, one 
may expect that these mutant p53 cells recover preferentially after exposure to 
chemotherapeutic drugs. To test this notion, each mutant p53 cells were subjected to a 
clonogenic survival assay with three different concentrations of etoposide (2.95 ug/ml, 
1.5 ug/ml, 0.7 ug/ml) or cisplatin ( 1.25 ug/ml, 0.6 ug/ml, 0.3 ug/ml). The drug treatment 
lasted for 48 hours. After the drug was washed away, the cells were passaged to measure 
their ability to form colonies, and grown for another 12 days. Colonies were 
subsequently stained with crystal violet stain and counted (Figure 9). Untreated cells 
became confluent about four days after replating cells (pictures not shown). In 
comparison, most cells treated with cisplatin or etoposide showed reduced colony 
formation, suggesting that etoposide or cisplatin treatment resulted in damage beyond 
recovery. Indeed, cells expressing p53 mutation at 143, 175, and 248 showed lower 
survival in etoposide, and the latter also in response to cisplatin. Interestingly, cells 
expressing R273H appeared to show increased resistance to both drugs. 
As shown in Figure I 0, counting of colonies revealed that cells expressing R273H 
had a slight selective survival advantage over vector control cells when they were treated 
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Figure 9. Clonogenic survival assay of cells expressing different p53 mutants. Untreated control dish's staining pattern 
(not shown) showed that equal number of cells were plated for each mutant. After treating the cells with etoposide and 
cisplatin at three different concentrations (as listed above) for 48 hours, cells were washed and split into two culture dishes. 
They were allowed to resume growth for another two weeks. They were stained with crystal violet stain, and the number 
of stained colonies was counted. 
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with a low concentration of etoposide (0.7 ug/ml). This survival advantage is not shown 
when cells were treated with a higher concentration of etoposide. Surprisingly, other 
mutants (R248W, Rl75H, and Vl43A) showed a statistically significant degree of 
sensitization to the effects of etoposide, forming fewer colonies than the vector control 
cells. 
Quantitative clonogenic survival assays with cisplatin showed slightly different 
results (Figure 11 and 12). Cells expressing R273H showed a statistically significant 
survival advantage over vector control cells when they were treated with 0.6 ug/ml 
cisplatin (Figure 12). Other mutants did not differ significantly from vector control 
except for R248W, which showed sensitization to cisplatin. All of the mutant p53 cells 
treated with 1.25 ug/ml of cisplatin formed very few colonies, characterizing the cell 
survival concentration limit for cisplatin. In contrast, most of the mutant cells became 
almost confluent on l 0cm dishes after 1 2  days of recovery when they were treated with 
0.3 ug/ml of cisplatin. Cells expressing R248W, however, showed dramatic reduction in 
the number of surviving colonies even at this concentration, indicating sensitization to 
cisplatin (Figure l O and 11 ). Taken together, these results imply that overexpression of 
R273H provided a survival advantage to AST 11.9 cells exposed to cytotoxic drugs such 
as etoposide and cisplatin. Moreover, this effect seems to be concentration specific. In 
contrast, overexpression of R248W conferred sensitization to etoposide and cisplatin. In 
either event, mutant p53 cells behave differently from vector control cells, indicating the 
gain of function characteristics of mutant p53. 
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Figure 10. Each data point represents the average of three separate experiments. Each color bar represents mutations at 
different codons of p53 protein. Number of surviving colonies are counted 14 days after the treatment with etoposide at 
three different concentrations (2.95 ug/ml, 1.5 ug/ml, 0.7 ug/ml). 
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different codons of p53 protein. Number of surviving colonies are counted 14 days after the treatment with cisplatin at 
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Discussion 
Clonogenic survival and apoptosis assays with etoposide and cisplatin provided 
some evidence for gain function activity of mutant p53 proteins. Results showed that 
overexpression of R273H renders protection and survival advantages to AST 11.9 cells 
treated with etoposide or cisplatin. Overexpression of R248W, however, caused 
sensitization to both etoposide and cisplatin. These could not be characterized as 
dominant negative functions by mutant p53 proteins because ASTl 1.9 cells did not 
express endogenous wild type p53. Furthermore, p53 mutant cells showed significantly 
different response to cytotoxic drugs compared to vector control cells, which represented 
loss of function. Therefore, the protective effects against cytotoxic drugs seem to be gain 
of function by mutant p53 proteins. 
The evidence that R273H confers resistance is weakened by the large error bars 
(Figures 10-12). However, each experiment showed similar crystal violet staining 
patterns as shown in Figure 9 and only differed in overall density of colonies. AST 11. 9 
cells expressing mutant p53 appeared to change their characteristics over time in culture 
including increased growth rate and cellular transformations, requiring replacement of 
cells after about ten passages. This may be due to genomic instability that is associated 
with p53 mutant cells5· 32· 33. These cells lack the GI cell cycle check point which allows 
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an increased mutation rate. Future experiments with the same passage of cells may 
resolve this issue. 
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Survival advantages shown by expression of R273H may be dependent on the 
concentration of drug used to challenge the cells. Expression of R273H gave a survival 
advantage to cells treated with a low concentration (0.7 ug/ml)of etoposide, but not when 
they were treated with higher concentrations (2.95 ug/ml and 1.5 ug/ml) of etoposide. 
Similar results were seen with the cisplatin treatment. Most of the cells were dead two 
weeks after high concentration treatment with cisplatin ( 1.25 ug/ml). In comparison, 
treatment with 0.6 ug/ml of cisplatin showed a significant survival advantage by cells 
overexpressing R273H. Treatment with 0.3 ug/ml of cisplatin, however, did not show 
any difference. This suggests that low concentrations of drug may not kill cells (i.e. 
induce apoptosis) but may induce permanent growth arrest, preventing these cells from 
fom1ing colonies. High concentration of drug, however, may induce apoptosis, causing 
dramatic reduction in colony formation or no survival at all. 
In addition to drug concentration dependence, comparing the results from the 
apoptosis assays and the clonogenic survival assays showed that short-term resistance to 
high concentration of drug may not translate into a long term survival advantage. 
Quantitative apoptosis assays results showed that cells expressing R273H may be 
resistant to the highest concentration of etoposide used (5.9 ug/ml). However, when they 
were allowed to recover for another JO day (without replating them to a new dish), cells 
in the dish did not resume growth suggesting that these cells were no longer mitotically 
active. Furthermore, expression of R273H did not bestow a survival advantage on 
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astrocytes when they were treated with a higher concentration of etoposide (2.5 ug/ml) in 
the clonogenic survival assay. Rather, only the cells treated with low concentrations of 
etoposide (0.7 ug/ml) showed a survival advantage. Experiments with cisplatin showed 
similar results with cells expressing R273H. This suggests that the ability of cells to 
show short term resistance to drug does not translate into the ability of cells to establish a 
new clone after treatment with drug. 
Other studies also have shown similar results. Murine p53-null myeloblastic 
cells exhibited an increased resistance to doxorubicin and cisplatin upon expression of 
Al35V27 . Human p53-null Saos-2 cells survived treatment with cisplatin significantly 
better when expressing Vl43A, RI 75H, or R273H28 . Finally, human p53-null lung 
carcinoma cells producing R 175H or R 179H were protected from apoptosis induced by 
etoposide 19 . The same study also demonstrated that lung carcinoma cells expressing p53 
mutants did not protect from apoptosis when they were treated with a high concentration 
of cisplatin ( 1 Oug/ml). These studies not only confirms anti-apoptotic gain of function in 
some tumor cell systems, but it also shows that specific mutations that confer this 
protective effect may depend on cell type and drug under study. 
Enhanced drug sensitivity by mutant p53 proteins is shown in K562 leukemia 
cells when the temperature sensitive p53 A 135V was expressed in the mutant 
conformation29. In addition, LN-308 p53-null glioma cells expressing Al35V showed 
enhanced sensitivity to BCNU and cytarabin but increased resistance to teniposide21 • Our 
results with R248W also confirmed the notion that certain mutations in p53 may sensitize 
cells to chemotherapy. These results suggest that certain p53 mutants may have residual 
wild type activity. This residual wild type activity by mutant p53 is shown in other 
cellular functions. For example, it was found that purified wild-type human p53 and 
mutant R273H were equivalent in their enhancement of human topisomerase 130 . It is 
interesting to note that both R248W and R273H do not change the wild type's tertiary 
conformation but the wild type's ability to bind to DNA, suggesting that retaining the 
wild type conformation may be important to their ability to hold residual wild type 
activity. 
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Mechanisms on how these p53 mutant proteins modulate chemosensitivity is 
currently unknown. Our results have shown that survival advantage by R273H is at least 
not affected by growth rate. However, the growth rate experiment was done with the 
optimal growth conditions provided by high concentrations of serum. Whether mutant 
p53 enhances growth in conditions of low serum in vivo remains to be explored. It is 
also interesting to point out that both R273H and R248W are mutations that effect direct 
contact with DNA without altering the overall tertiary structure of p53. However, others 
studies have proved that conformational mutant p53 proteins such as R 175H protect cells 
from apoptotic effects of etoposide and cisplatin 19. This implies that both types of mutant 
p53 proteins are involved with modulation of chemosensitivity. 
It is known that mutant p53 proteins can transactivate specific genes. For 
example, elevated level of certain ribosomal protein genes were detected in the presence 
of the human colon carcinoma-derived R248W in murine p53-null fibroblasts31. 
Moreover, wild type p53 has been shown to regulate the levels of some ribosomal protein 
genes31
• It may be possible that mutant p53 retain certain functions of wild type p53 by 
transactivating some of the same genes. 
33 
In conclusion, our findings suggest that the presence of certain p53 mutations may 
render a tumor less responsive to particular type of chemotherapy. However, some p53 
mutations may enhance effectiveness of certain chemotherapuetic drugs. Eventually, the 
knowledge of whether mutant p53 can inhibit or sensitize apoptosis induced by specific 
chemotherapeutic drugs could be clinically important in the decision of which mode of 
therapy may be suitable for each individual cancer expressing a particular type of p53. 
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